Clozapine Tablets USP — Class II drug recall D-0096-2018
Terminated recall by Teva Pharmaceuticals USA, reported 2017-12-06, distributed nationwide. Failed Tablet/Capsule Specifications; potential presence of broken tablets.
| Recall number | D-0096-2018 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Teva Pharmaceuticals USA, North Wales, PA, United States |
| Recall initiated | 2017-11-09 |
| Classified | 2017-11-27 |
| Reported by FDA | 2017-12-06 |
| Terminated | 2018-07-03 |
| Distributed | Nationwide (US) |
| Quantity | 3,870 bottles |
| NDC | 00093-7772-05 |
| Lot numbers | 39C192 |
| Expiration dates | 2019-06 |
Product
Clozapine Tablets USP, 100 mg, 500 count bottles, Rx only, Manufactured in Israel by: TEVA PHARMACEUTICALS IND, LTD, Jerusalem Israel, Manufactured For: TEVA PHARMACEUTICALS USA, North Wales, PA, NDC 00093-7772-05
Reason for recall
Failed Tablet/Capsule Specifications; potential presence of broken tablets.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0096-2018. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.